| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 112 | -667 |
| Depreciation and amortization | 3,249 | 2,168 |
| Stock-based compensation | 5,002 | 3,046 |
| Goodwill impairment | 0 | - |
| Bad debt expense | 0 | 0 |
| Amortization of debt issuance costs | 785 | 611 |
| Accounts receivable | -5,985 | -4,700 |
| Prepaid expenses and other assets | 448 | 958 |
| Accounts payable | -119 | -174 |
| Revenue share payable | -2,724 | -2,462 |
| Accrued expenses and other liabilities | 1,913 | 4,138 |
| Operating lease liabilities | 15 | 9 |
| Deferred tax liabilities | 0 | 1,033 |
| Taxes receivable and payable | -2,065 | -964 |
| Deferred revenue | -78 | 11 |
| Net cash provided by operating activities | 11,627 | 8,425 |
| Purchase of property and equipment | 47 | 37 |
| Capitalized software development costs | 91 | 91 |
| Net cash used in investing activities | -138 | -128 |
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | 188 | - |
| Proceeds from exercise of stock options | 338 | - |
| Repayment of long-term debt | 5,500 | 5,000 |
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | - | 92 |
| Net cash used in financing activities | -5,350 | -5,092 |
| Net increase in cash and cash equivalents | 6,139 | 3,205 |
| Cash and cash equivalents at beginning of period | 13,380 | - |
| Cash and cash equivalents at end of period | 19,519 | - |
OptimizeRx Corp (OPRX)
OptimizeRx Corp (OPRX)